Biocatalytic technology has become an increasingly important strategy for pharmaceutical and biotechnology companies seeking more selective, efficient, and development-friendly synthetic routes for complex molecules. Enzyme-enabled transformations can simplify route design, improve stereocontrol, and reduce the burden of harsh reaction conditions when conventional chemistry struggles with regioselectivity, chemoselectivity, or challenging chiral centers. BOC Sciences provides integrated biocatalytic technology services spanning enzyme screening, biotransformation feasibility assessment, enzyme engineering, reaction optimization, immobilization strategy development, cofactor regeneration design, and scalable process implementation. Our team supports clients across hit expansion, lead optimization, route scouting, intermediate preparation, and advanced API process development, helping accelerate decision-making while improving route robustness, yield potential, and manufacturability.
We assess enzymatic options for difficult transformations, including asymmetric reduction, selective oxidation, hydrolysis, amination, and C-C or C-N bond-forming steps, enabling faster route selection for complex pharmaceutical targets and lead optimization programs.
For substrates with limited native enzyme compatibility, we optimize catalytic performance through sequence refinement, activity enhancement, substrate scope tuning, and stability improvement to unlock more productive biocatalytic routes.
We design practical regeneration and catalyst handling strategies to improve economics, operational stability, and reuse potential in preparative and scale-oriented biocatalytic processes.
We translate promising enzyme reactions into robust development workflows, integrating upstream catalyst preparation, reaction engineering, and downstream isolation for chiral synthesis and advanced intermediate production.
BOC Sciences helps drug developers apply enzyme-enabled chemistry to improve selectivity, streamline routes, and create scalable solutions for high-value molecules.
We build fit-for-purpose screening campaigns to identify viable enzyme classes, reaction conditions, and substrate compatibility profiles quickly, enabling informed route selection for early and mid-stage pharmaceutical programs.
Our development workflows improve enzyme activity, selectivity, and robustness for non-natural substrates, helping convert promising biotransformations into practical synthesis tools for medicinal and process chemistry.
We design efficient recycling schemes for cofactor-dependent reactions to improve catalyst productivity, reduce consumable burden, and support more economical implementation of redox-intensive transformations.
For suitable reaction classes, we evaluate continuous processing approaches that enhance catalyst utilization, improve heat and mass transfer, and enable more controlled execution of multistep biocatalytic sequences.
We investigate immobilized catalyst formats to extend operational lifetime, simplify separation, and improve reproducibility in repeated-use or longer-duration biocatalytic manufacturing campaigns.
Our team combines biocatalytic and synthetic organic chemistry steps into coherent development plans, enabling clients to capture the selectivity of enzymes without sacrificing route flexibility.
BOC Sciences supports a broad range of pharmaceutical substrates, intermediates, and target molecules suitable for enzymatic and chemoenzymatic development. Our teams design biocatalytic strategies around the structural complexity, stereochemical demands, and process objectives of each client program.
Share your target structure, bottleneck step, or current synthetic route. Our scientists will evaluate where biocatalytic technology can improve selectivity, simplify processing, and strengthen route scalability.
We review your target molecule, synthetic bottlenecks, stereochemical requirements, substrate liabilities, and desired output profile to identify where biocatalysis can create the greatest technical and commercial advantage.
Candidate enzymes are screened under tailored reaction conditions, followed by systematic optimization of pH, temperature, substrate loading, co-solvent composition, cofactor balance, and reaction time to maximize conversion and selectivity.
When required, we refine enzyme performance, evaluate immobilization or recycling strategies, and integrate biocatalytic steps into broader synthetic workflows suitable for preparative synthesis or larger-scale process transfer.
We finalize workup and purification strategies, deliver the target intermediate or compound, and provide clear technical documentation covering catalyst choice, process rationale, and development outcomes.
Many drug candidates require highly controlled stereochemistry that is difficult to achieve efficiently using traditional synthetic routes. BOC Sciences applies enzyme-driven reduction, amination, hydrolysis, and desymmetrization strategies to access chiral products with excellent selectivity, helping clients simplify downstream purification and reduce route complexity for demanding chiral analysis and separation objectives.
Pharmaceutical intermediates often fall outside the preferred substrate space of native enzymes. We address this through targeted screening, catalyst refinement, and reaction engineering, creating more productive systems for heterocyclic, halogenated, sterically hindered, or otherwise challenging medicinal chemistry substrates.
Redox biocatalysis can be limited by cofactor costs and catalyst instability if the system is not designed carefully. Our teams develop regeneration strategies, immobilization options, and practical operating modes that improve enzyme longevity, strengthen process economics, and support more reliable scale-oriented implementation.
Successful deployment of biocatalysis depends on fitting the enzymatic step into the broader route, not treating it as an isolated experiment. We design chemoenzymatic workflows that balance substrate preparation, enzyme compatibility, impurity control, and isolation efficiency, reducing development friction across multidisciplinary programs.
Work with BOC Sciences to evaluate enzyme-enabled routes for selective synthesis, chiral intermediate preparation, and scalable process development tailored to modern pharmaceutical pipelines.
We deploy biocatalytic strategies where enzymes can deliver meaningful gains in regioselectivity, chemoselectivity, and stereocontrol for complex drug-like molecules.
Our work goes beyond proof-of-concept activity screening. We focus on route fit, reaction robustness, catalyst handling, and isolation practicality to support real pharmaceutical development needs.
We combine enzyme screening, engineering, immobilization, and chemoenzymatic planning into tailored workflows that align with your molecule, timeline, and synthetic objectives.
Our scientists evaluate substrate structure, reactivity constraints, impurity risks, and downstream process implications so that each biocatalytic solution is built around the realities of pharmaceutical chemistry.
Client Needs: A drug discovery client required a scalable route to a heteroaryl chiral amine intermediate used in a kinase inhibitor program. Their existing chemical reduction approach generated a difficult stereoisomeric mixture and created a purification-intensive workflow.
Challenges: The substrate featured a sterically congested ketone adjacent to a nitrogen-rich aromatic system, limiting catalyst compatibility and making conventional asymmetric reduction inefficient at preparative scale.
Solution: BOC Sciences screened multiple transaminase and ketoreductase panels, then optimized a biocatalytic amination route with tailored pH control, amine donor balance, and substrate feeding. To improve substrate handling, we also evaluated co-solvent tolerance and adjusted reaction temperature to preserve enzyme activity while maintaining acceptable substrate concentration. In parallel, our team refined the workup sequence through phase adjustment and selective extraction, which helped suppress impurity carryover, reduce by-product accumulation, and strengthen isolated product quality across repeat runs.
Outcome: The redesigned route delivered the target chiral intermediate with high stereoselectivity, simplified purification, and a markedly more development-friendly process suitable for continued route advancement.
Client Needs: A biotech partner needed a selective oxidation step for a polar, multifunctional small molecule related to a metabolite identification program. Chemical oxidation generated multiple over-oxidized and off-target products.
Challenges: The substrate contained both benzylic and heteroatom-adjacent reactive sites, requiring precise control over reaction selectivity while preserving a sensitive side chain important for downstream analytical comparison.
Solution: We developed a biocatalytic oxidation workflow using a carefully selected oxidoreductase system with a matched cofactor recycling module. Reaction parameters, dissolved oxygen handling, and quench conditions were tuned to improve conversion while limiting side-product formation. To increase process consistency, we further optimized substrate addition mode and buffer composition, reducing localized over-oxidation during the early reaction phase. Product identity support was aligned with metabolites synthesis needs, and the isolation strategy was adjusted to better preserve the desired oxidized species during post-reaction handling.
Outcome: The process delivered the desired oxidized product with substantially improved site selectivity, enabling efficient access to a high-value reference compound for further pharmaceutical investigation.
Client Needs: A process development team sought a more sustainable and reusable enzymatic approach for a NADPH-dependent reduction step in the synthesis of a fluorinated alcohol intermediate for a CNS program.
Challenges: Soluble catalyst use led to limited operational lifetime, while cofactor consumption and difficult post-reaction handling reduced the attractiveness of the otherwise selective biotransformation.
Solution: BOC Sciences evaluated immobilized enzyme formats, selected a robust carrier system, and implemented a coupled cofactor regeneration design. We optimized agitation, substrate concentration, and recycle conditions to preserve catalyst productivity across repeated runs while maintaining conversion consistency. Additional studies were carried out to compare support loading and wet-state stability, allowing us to identify an immobilization format that balanced activity retention with practical reuse. We also refined filtration and catalyst recovery steps to minimize mechanical loss during turnover between batches, improving the overall operability of the reduction workflow.
Outcome: The immobilized redox system improved catalyst reusability, simplified phase separation, and provided a more practical development route for scale-up consideration.
Biocatalytic technology is increasingly valued in modern drug development because it offers high selectivity, mild reaction conditions, and clearer process logic when working with structurally complex molecules. For projects involving chiral center construction, metabolic stability optimization, or route simplification, enzyme-catalyzed transformations can help reduce unnecessary protection and deprotection steps while minimizing side reactions. This makes biocatalysis especially useful for medicinal chemistry, process research, and key intermediate synthesis in programs where molecular precision and synthetic efficiency are critical.
One of the main advantages of biocatalysis in chiral drug synthesis is its ability to deliver highly stereoselective transformations, helping development teams access desired isomers more efficiently. Compared with traditional chemical methods that may rely on complex chiral ligands or multi-step resolution strategies, biocatalytic approaches can often enable direct asymmetric reduction, oxidation, amination, or hydrolysis. For pharmaceutical R&D customers, this supports a more streamlined synthetic route and a more robust strategy for developing chiral intermediates and active compounds across different stages of drug development.
Drug development projects that involve highly selective transformations, complex scaffold functionalization, chiral intermediate preparation, or route optimization are often strong candidates for biocatalytic support. This is especially true when conventional synthetic routes are too long, when regioselectivity is difficult to control, or when yield and by-product issues complicate route selection. As a drug development service provider, BOC Sciences can support customers with integrated solutions covering enzyme screening, reaction optimization, and customized development strategies based on substrate characteristics and project goals, helping teams identify practical and scalable biocatalytic routes more efficiently.
Biocatalysis can play an important role in optimizing complex API synthesis routes, not only as a replacement for a single reaction step but also as a strategic element within a broader synthetic sequence. When a project faces challenges such as poor chemical selectivity, inefficient route design, or unstable key transformations, enzyme-based methods can open up new options for route improvement. By combining biocatalysis with conventional organic synthesis, teams can improve route flexibility and solve bottlenecks more effectively. BOC Sciences can support this process through substrate compatibility assessment, enzymatic reaction development, and route integration studies tailored to pharmaceutical development needs.
For professional drug development customers, selecting a biocatalysis service partner should involve more than evaluating access to enzyme resources alone. It is important to assess whether the provider can solve development challenges in a project-oriented way, including understanding pharmaceutical molecular structures, designing appropriate enzymatic strategies, integrating biocatalysis into synthetic routes, and aligning technical work with downstream process goals. A strong service partner should help answer not only whether a reaction is feasible, but whether it is suitable for long-term development. With experience supporting pharmaceutical R&D programs, BOC Sciences provides biocatalysis solutions that are more closely aligned with practical development needs and customer decision-making.
BOC Sciences did not just test enzymes randomly. Their team understood our route constraints, identified where biocatalysis would add the most value, and turned a problematic stereochemical step into a much cleaner development path.
— Head of Chemical Synthesis, a U.S. pharmaceutical company
We brought them a substrate that showed poor compatibility with our internal catalyst set. Their screening and optimization work quickly clarified the feasible transformation window and gave us a practical route we could move forward with.
— Senior Scientist, a European small molecule drug developer
What impressed us most was their process perspective. They considered catalyst reuse, cofactor management, and downstream isolation from the start, which made the biocatalytic solution much more realistic for our program.
— Director of Process Development, a U.S. biotech company
Our project involved a highly selective transformation that conventional chemistry handled poorly. BOC Sciences provided a thoughtful enzyme-based strategy and transparent technical communication throughout the study.
— Principal Scientist, a European drug discovery company
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
